Category: Hot Mandates

Hot Investor Mandate 2: Subsidiary of Large Pharmaceutical Looking for Innovative Therapeutic Companies Developing Treatments for Rare Blood Diseases

~ Next Phase Admin ~ Leave a comment

A fully owned subsidiary of a large pharmaceutical that focuses on treating rare blood diseases. The company partners with and invests in early stage companies in the blood disease field using a variety of structures. The company is open to partnering with companies worldwide.

The company is focused solely on rare blood diseases, including hemophilia, sickle cell disease, cold agglutinin disease, and beta thalassemia; the firm will consider assets in any rare blood disease, but does not consider blood cancers or blood-born pathogens. The company will consider assets from the very early idea stage through to commercial products. In addition to any therapeutic drugs that treat blood diseases, the company is also interested in other modalities such as medical devices, wearables and digital technologies that help treat or manage blood diseases.

The company is open to working with companies and researchers from a very early stage; for companies that do not yet have a complete management team, the company may take an active role in building a team or guiding development.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate 3: Venture Capital Firm with Strong Connections to China Seeks to Invest in Global, Early-Stage Biotech Companies with Opportunistic Outlook

~ Next Phase Admin ~ Leave a comment

A venture capital firm founded in 2014 has an office in the West Coast with its parent company based in Hangzhou, China. The firm currently has invested in over 39 companies across a wide variety of sectors including biotech, IoT, AI, etc. The firm’s strong connection with Chinese partners enables the firm to support companies with market entry in China. The firm is currently allocating out of its first fund of $20M and prefers to participate in seed/pre-series A financing rounds with check sizes of no larger than $500K.

The firm is currently raising a second fund with a target size of $50M, through which the firm hopes to invest more capital in later rounds (i.e. Series A to B) and provide follow on investments to portfolio companies. Through the second fund, the firm is also seeking to expand their interests in diagnostics, digital health, and novel therapeutics. Early in 2018, the firm has launched an accelerator program to support the growth of early-stage companies in the sectors mentioned above and provide these companies with valuable resources. The firm seeks investment opportunities globally.

The firm is opportunistic and will seek companies in all parts of the life sciences space: therapeutics, medical devices, diagnostics, healthcare IT, etc. The firm has not invested in therapeutic products so far but is actively seeking new opportunities in the biopharma space, focusing on pre-clinical to phase I assets. The firm focuses on early-stage deals and will consider pre-FDA device products. The firm is open to companies developing products in all indications.

The firm seeks to work with privately owned companies with experienced management teams with a track record of success. The firm likes to see companies with intentions of entering the China market as the firm has a network of resources to support this, but this is not a requirement. The firm generally acts as the co-investor in financing rounds.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate 4: Corporate Venture Arm of Global Pharma Seeks Therapeutics Companies with Focus on Pre-IND Assets in All Indications

~ Next Phase Admin ~ Leave a comment

A financially driven corporate life science venture fund of a global pharmaceutical company, invests with the purpose of fostering innovation, driving significant patient benefit, and generating superior returns by creating and investing in innovative life science companies at various stages of their development, independent from the corporate’s strategy. The firm has offices in USA and Europe, and focuses its investment activities in these countries. The firm typically makes equity investments in early venture rounds, investing up to $25 million over multiple financing rounds with 6-8 investments in any given year.

The firm invests in therapeutics with a focus on pre-IND assets and Series A investment rounds. The firm is interested in all classes and indications of innovative therapeutics with paradigm shifting potential.

The firm invests exclusively in privately held companies and aims to be a lead or co-lead with a director position.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate 1: China-Based VC Firm Can Invest Up to $50M in Life Science Companies, Including Therapeutics, Medical Devices, Diagnostics, and Digital Health

~ Next Phase Admin ~ Leave a comment

A venture firm based in China with offices in the West and East Coast currently funds healthcare companies out of their $3.5B fund. The firm is interested in companies raising their seed to Series A rounds and provides investments that can range from $5M to $50M depending on the opportunity. The firm seeks opportunities globally, though has a preference on companies based in China.

The firm is interested in therapeutics, medical devices without drug components, in-vitro diagnostics, and healthcare IT. The firm is interested in preclinical to early-stage clinical (Ph I-II) technologies. The firm is indication agnostic, though highly prefers technology with a China market angle.

The firm does not have a management team requirement, and will help support early-stage companies with filling management teams, if necessary.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate 2: Sister Fund to USA-Based Biotech Focused Investment Firm Invests Up to $20M in Therapeutics, Medical Devices with Strong China Angle

~ Next Phase Admin ~ Leave a comment

A newly established sister fund to a USA based biotech focused fund looks to fund companies either based in China or with a strong China angle. The firm will invest 60-70% of its funds in therapeutics, with the rest in medical devices. For most of its investments, the firm will invest around $20M in Seed to Series A rounds for a majority stake in the company, in addition to taking active part in the company. Occasionally, the firm will make a minority investment in a company, no later than Series B, but is by no means a passive investor. The firm is looking for companies with technologies either in development or in clinical trials, unless based in China, in which case the company’s lead candidate must already be in clinical trials.

While fairly agnostic to subsector and indication, the firm is interested in therapeutics and medical devices that are relevant to the Chinese market. Of particular interest are technologies related to oncology indications common to China, ophthalmic indications, neurodegenerative diseases, and women’s health and fertility.

The firm is looking to take a majority share in most of its portfolio companies, followed by active involvement in company management. In all cases the firm looks to be an active investor. The company must have a China angle, whether it has headquarters or offices there, or is pursuing the Chinese market or clinical trials in China.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate 3: USA Venture Firm Seeks to Invest in Innovative Digital Health and Software-Based Diagnostic Companies

~ Next Phase Admin ~ Leave a comment

A venture capital firm with multiple offices in the USA is looking to invest in tech-driven companies that have at least one female on the leadership team. The firm invests in technology companies, including those in the healthcare sector, such as digital health and software-based diagnostics companies. The firm will invest primarily in series A-B rounds in USA-based companies with at least $1M in revenue. The firm will typically make initial investments between $1.5-5M.

The firm invests in technology companies in the digital health space that are solving some of the world’s greatest challenges. The firm particularly likes to see companies that are creating more affordable health solutions.

The firm does not require a board seat when investing, but may take one if the firm leads an investment round.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate 4: Japanese Pharmaceutical with Established USA Subsidiary Seeks Innovative Early-Stage Therapeutics Assets in Neurodegenerative & Neurodevelopmental Diseases

~ Next Phase Admin ~ Leave a comment

A multinational pharmaceutical company headquartered in Japan is actively looking globally for opportunities to in-license cutting-edge, early stage therapeutic assets. The pharma also has a large USA-based subsidiary. Sponsored research may also be considered with a focus on Japan-based academic institutions.

The firm’s external R&D is focused on both neurodegenerative and neurodevelopmental diseases including Parkinson’s disease, autism, Rett Syndrome, fragile X, and lysosomal storage diseases. The firm is interested in platform technology and early stage hits/seeds in CNS/neurology. This includes new MOAs such as gene therapy, stem cell therapy, BBB penetrating biologics and monoclonal antibodies acting on new targets. The firm is also interested in later-stage assets (phase III to on the market) in diabetes, immunology, and infectious diseases for the Asia markets.

The firm is looking for assets that would be strategic a fit with its current portfolio. The firm is willing to negotiate regional rights based each therapeutic field. For example, in immunology and neurology, the firm would prefer both US and Asia rights. In diabetes, infectious diseases, and other areas, the firm can request Asia rights only.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.